Future prospects in immunosuppression for liver transplantation

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  Fung, John J ^a   Bollinger, Jessica E ^a   Miller, Charles ^a   Eghtesad, Bijan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN A; EFALIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SOTRASTAURIN; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TOFACITINIB; TOL 101; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; BLOOD PRESSURE; CELL INTERACTION; DIABETES MELLITUS; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERNALIZATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIVER TRANSPLANTATION; METABOLIC DISORDER; NEUTROPENIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; T CELL DEPLETION; IMMUNOLOGY; REVIEW;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 84857172790     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22412     Document Type: Article

References (26)

1. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005;11: 267-280.
2. Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of aphase II clinical trial. Transplantation 1997;64: 274-281.
3. Tanaka S, Yamazaki M, Okamoto Y. Determination of advanced glycation end-products on IgG in liver cirrhosis. Hepatogastroenterology 2009;56: 1735-1737.
4. Budde K, Sommerer C, Becker T, Asderakis A, Pietruck F, Grinyo JM, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renaltransplant recipients. Am J Transplant 2010;10: 571-581.
5. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011;11: 1444-1455.
6. Kovarik JM, Neuhaus P, Cillo U, Weber M, Stitah S, Gatlik E, et al. Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients. Transpl Int 2011;24: 276-283.
7. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, et al.; for Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353: 770-781.
8. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept- based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10: 535-546.
9. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFITEXT studies). Transplantation 2011;91: 976-983.
10. Garcia-Valdecasas JC, Feng S, Lake JR, Vargas HE, Wekerle T, Meadows-Shropshire S, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study [abstract]. Liver Transpl 2011;17(suppl 1): S79.
11. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, et al. A phase I/II randomized openlabel multicenter trial of efalizumab, a humanized anti- CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007;7: 1770-1777.
12. US Food and Drug Administration. FDA public health advisory updated safety information about Raptiva (efalizumab). http: //www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/Public HealthAdvisories/ ucm110605.htm. Accessed August 2011.
13. Shapira MY, Resnick IB, Dray L, Aker M, Stepensky P, Elad S, et al. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 2009;11: 61-67.
14. Rostaing L, Mourad M, Charpentier B, Glyda M, Rigotti P, Falk F, et al. Efficacy and safety of alefacept in combination with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation [abstract]. Am J Transplant 2011;11(suppl 2): 98.
15. Lo DJ, Weaver TA, Stempora L, Mehta AK, Ford ML, Larsen CP, Kirk AD. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011;11: 22-33.
16. Stotler CJ, Eghtesad B, Hsi E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood 2009;113: 5365-5366.
17. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am JTransplant 2009;9: 1936-1945.
18. Sewgobind VD, Quaedackers ME, van der Laan LJ, Kraaijeveld R, Korevaar SS, Chan G, et al. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant 2010;10: 1785-1795.
19. Nafady-Hego H, Li Y, Ohe H, Zhao X, Satoda N, Sakaguchi S, et al. The generation of donor-specific CD4+CD25++CD45RA+ naive regulatory T cells in operationally tolerant patients after pediatric livingdonor liver transplantation. Transplantation 2010;90: 1547-1555.
20. Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, et al.; for RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5: 2521-2530.
21. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, et al.; for B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80: 244-252.
22. Saliba F, De Simone P, Nevens F, De Carlis L Metselaar HJ, Beckebaum S, et al. Efficacy and safety of everolimus with early reduction or elimination of tacrolimus in 719 de novo liver transplant recipients: 12 month results of a randomized, controlled study. Hepatology 2011;54 (Suppl); in press.
23. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci 1997;94: 8789-8794.
24. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381: 434-438.
25. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6: 114.
26. Aoyagi T, Yamashita K, Suzuki T, Uno M, Goto R, Taniguchi M, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am a Transplant 2009;9: 1732-1741.